Javier Martinez-Trufero

Associated Proffesor

Universidad de Murcia Facultad de Medicina

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Javier Martinez-Trufero is an Associated Professor at Universidad de Zaragoza Facultad de Medicina, Spain. His research areas include the management of sarcomas, pharmacogenetics in chemotherapy, and palliative care for cancer patients. Recent publications address the effects of mitotane in adrenocortical carcinoma, clinical guidelines for soft-tissue sarcomas, and innovative treatment combinations in advanced sarcoma cases.

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Vittorio Lorenzo Quagliuolo

Chief

IRCCS Humanitas Research Hospital

ITALY

View details

Maria Plana

Institut Català d'Oncologia

SPAIN

View details

Javier Martín-Broto

SPAIN

View details

Emanuela Palmerini

University of Toronto

ITALY

View details

Rogelio García-Centeno

Facultativo Especialista en Endocrinología. Profesor asociado Universidad Complutense de Madrid

Gunma University Hospital

SPAIN

View details

Ibon Gurruchaga Sotés

Profesor Asociado

Universidad de Navarra

SPAIN

View details

Maria J Arranz

Head

SPAIN

View details

Jose Manuel Asencio

Complutense University

SPAIN

View details

Sebastian Bauer

Professor / Chair

Universität Duisburg-Essen

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Javier Martinez-Trufero

Research Interests

Explore related searches

Contact this professor

About

Articles (26)

Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024).

Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial

Predictive and dynamic signature for anti-angiogenics in combination with PD-1 inhibitor in soft-tissue sarcoma: correlative studies linked to the IMMUNOSARC trial.

Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor.

Spontaneous remission of a pulmonary sclerosing epithelioid fibrosarcoma: a case report of a possible abscopal effect.

HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

Analysis of the Complexity of Palliative Care for Cancer Patients

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain.

Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.

Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)

Sequential therapy with induction chemotherapy and chemoradiotherapy in pre-irradiated recurrent head and neck squamous cell carcinoma incorporating nab-paclitaxel-a commentary of the phase I trial of AFHX followed by concomitant FHX scheme.

Corrigendum to 'Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study' [Eur J Cancer 171 (2022) 183-192].

Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

Survival differences of patients with resected extraskeletal osteosarcoma receiving two different (neo)adjuvant chemotherapy regimens: a systematic review and meta-analysis

Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer

Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

Collaborators (9)

Vittorio Lorenzo Quagliuolo

Maria Plana

Javier Martín-Broto

Emanuela Palmerini

Rogelio García-Centeno

Ibon Gurruchaga Sotés

Maria J Arranz

Jose Manuel Asencio

Sebastian Bauer

Make your next move.